Physician profile
Wei Wang
NPI 1982090874
$3,130.73
in general payments reported to CMS, 2019-2025
17 companies · $662 in 2025
The $662 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $263 · 2020: $100 · 2021: $288 · 2022: $715 · 2023: $567 · 2024: $535 · 2025: $662.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,647 · Education: $117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,647.03 |
| Education | $117.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Pharmaceuticals, INC. | $619.38 | 2021-2024 | Eylea Hd |
| Regeneron Healthcare Solutions, INC. | $464.92 | 2019-2023 | Eylea |
| Genentech USA, INC. | $403.44 | 2022-2025 | Vabysmo, Susvimo |
| Apellis Pharmaceuticals, INC. | $250.97 | 2023-2025 | Syfovre |
| Mallinckrodt Hospital Products INC. | $244.68 | 2021-2025 | Acthar |
| Ani Pharmaceuticals, INC. | $229.32 | 2023-2025 | Purified Cortrophin Gel, Iluvien |
| Eyepoint US, INC. | $209.75 | 2022 | |
| Bausch & Lomb Americas INC. | $139.53 | 2022-2024 | Xipere |
| Alimera Sciences, INC. | $137.19 | 2021-2024 | Yutiq, Iluvien |
| Kala Pharmaceuticals, INC. | $119.70 | 2019 | |
| Novartis Pharmaceuticals Corporation | $110.43 | 2019-2020 | |
| Harrow Eye, LLC | $78.83 | 2025 | Triesence, Iheezo |
| Abbvie INC. | $65.90 | 2023-2025 | Ozurdex |
| Alcon Vision LLC | $27.49 | 2024 | Ngenuity |
| Amgen INC. | $15.24 | 2024 | Tepezza |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $13.96 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wei Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.